Introduction: History of the management of advanced renal cell cancer Janice P. Dutcher Editorial 14 January 2009 Pages: 1 - 2
The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma Antonio Romo de Vivar ChavezMichael E. de VeraMichael T. Lotze Original Paper 16 January 2009 Pages: 3 - 12
The application of high-dose interleukin-2 for metastatic renal cell carcinoma David F. McDermott Original Paper 16 January 2009 Pages: 13 - 17
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy Michael B. Atkins Original Paper 23 January 2009 Pages: 18 - 22
IL-2 in the therapy of melanoma and other malignancies Kim Margolin Original Paper 28 January 2009 Pages: 23 - 31
Mechanism of action of everolimus in renal cell carcinoma Bernard EscudierJohn A. Thompson Original Paper 28 January 2009 Pages: 32 - 39
Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways James M. G. LarkinRosemary E. J. ClarkeLisa M. Pickering Original Paper 14 January 2009 Pages: 40 - 45
Everolimus for renal cell carcinoma: predictive factors for response and future directions Guru SonpavdeThomas E. Hutson Original Paper 16 January 2009 Pages: 46 - 53
